[1] Halloran PF. Immunosuppressive drugs for kidney transplantation[J]. N Engl J Med, 2004,351(26):2715-2729.
[2] Krämer BK, Montagnino G, Krüger B, et al. Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation:7-year observational results[J]. Transpl Int, 2016,29(3):307-314.
[3] Ateyya H. Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin[J]. Int Immunopharmacol, 2015,28(1):571-577.
[4] Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy[J]. N Engl J Med, 2003, 349(24):2326-2333.
[5] Gau CH, Tu HP, Chin YT, et al. Can chlorhexidine mouthwash twice daily ameliorate cyclosporine-induced gingival overgrowth?[J]. J Formos Med Assoc, 2013,112(3):131-137.
[6] Wadei HM, Textor SC. Hypertension in the kidney transplant recipient[J]. Transplant Rev (Orlando), 2010,24(3):105-120.
[7] Rezzani R. Cyclosporine A and adverse effects on organs:histochemical studies[J]. Prog Histochem Cytochem,2004,39(2):85-128.
[8] Kamel M, Kadian M, Srinivas T, et al. Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine[J].World J Transplant,2016, 6(4):697-702.
[9] Franke GH, Trampenau C, Reimer J, et al. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation[J]. Transplant Proc, 2006,38(5):1293-1294.
[10] Videla CO. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy[J]. Transplant Proc, 2009,41(6):2659-2663.
[11] Margreiter R, Pohanka E, Sparacino V, et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects[J]. Transpl Int, 2005,18(7):816-823.
[12] 黄晓宁,陈小娟,李勇. 肾移植术后患者应用他克莫司与环孢素A发生急性排斥反应的Meta分析[J].中国医院用药评价与分析,2016,16(5):636-639.
[13] Tao Y, Hu L, Li S, et al. Tranilast prevents the progression of chronic cyclosporine nephrotoxicity through regulation of transforming growth factor β/Smad pathways[J].Transplant Proc,2011,43(5):1985-1988.
[14] Seeland S, Török M, Kettiger H, et al. A cell-based, multiparametric sensor approach characterises drug-induced cytotoxicity in human liver HepG2 cells[J]. Toxicol In Vitro, 2013,27(3):1109-1120.
[15] Cond SAP, Bastos MG, Vieira BJ, et al. Down-regulation of transforming growth factor beta-2 expression is associated with the reduction of cyclosporin induced gingival overgrowth in rats treated with roxithromycin:an experimental study[J]. BMC Oral Health,2009,9(1):33.
[16] Al-Hamilly NS, Radwan LR, Abdul-Rahman M, et al. Biological roles of KGF, CTGF and TGF-β in cyclosporine-A-and phenytoin-induced gingival overgrowth:A comparative experimental animal study.[J]. Arch Oral Biol,2016,66:38-43.
[17] 余爱华,辛华雯,吴笑春,等.环孢素和他克莫司对肾移植后发生糖尿病的影响研究[J]. 中国药师, 2011,14(4):521-523.
[18] Sinangil A, Celik V, Barlas S, et al. New-onset diabetes after kidney transplantation and pretransplant hypomagnesemia[J]. Prog Transplant, 2016, 26(1):55-61.